Navigation Links
Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
Date:5/23/2008

SUNRISE, Fla., May 23 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT) announced that on May 21, 2008 it received a letter from the Nasdaq Stock Market (the "Nasdaq Letter") advising that, for the last 10 consecutive trading days, the Company's market value of listed securities had been below the minimum $50,000,000 requirement for continued inclusion on The Nasdaq Global Market pursuant to Nasdaq Marketplace Rule 4450(b)(1)(A). Furthermore, Nasdaq stated that the Company does not comply with Nasdaq Marketplace Rule 4450(b)(1)(B), which requires the Company to have total assets and total revenue of $50,000,000 each for the most recently completed fiscal year or two of the last three most recently completed fiscal years. Compliance with either Nasdaq Marketplace Rule 4450(b)(1)(A) or 4450(b)(1)(B) is one of the minimum standards for continued inclusion on The Nasdaq Global Market.

In the Nasdaq Letter, Nasdaq advised that, in accordance with Nasdaq Marketplace Rule 4450(e)(4), the Company will be provided 30 calendar days, or until June 20, 2008 (the "Compliance Period"), to regain compliance with Nasdaq Marketplace Rule 4450(b)(1)(A).

In the event the Company determines that it is unable to regain compliance with Nasdaq Marketplace Rule 4450(b)(1)(A) during the Compliance Period, the Company intends to apply to transfer its common stock to the Nasdaq Capital Market on or before the end of the Compliance Period to seek to ensure that consistent and continual access to capital markets is maintained for all its shareholders. The Nasdaq Capital Market currently includes over 500 companies and operates in substantially the same manner as the Nasdaq Global Market. Securities listed on the Nasdaq Capital Market satisfy all applicable qualification requirements for Nasdaq securities and all companies listed on the Nasdaq Capital Market must meet certain financial requirements and adhere to Nasdaq's corporate governance standards.

About Bioheart, Inc.

Bioheart, Inc. is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative muscle stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose-tissue derived stem cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic proteins.

(MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.)

Contact: William Kline Lytham Partners, LLC

Chief Financial Officer Joe Diaz

Nicholas Burke Joe Dorame

VP - Financial Operations Robert Blum

(954) 835-1500 (602) 889-9700


'/>"/>
SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
2. Bioheart, Inc. Announces Financial Results for First Quarter 2008
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... ... Clinical Supplies Management (“CSM”), a Great Point Partners II (“GPP”) portfolio company, ... has doubled in size over the past six months with the acquisition of businesses ... joins CSM as Chief Financial Officer. Roger has over 25 years of experience ...
(Date:5/18/2017)... ... 17, 2017 , ... Cognition Corporation ( http://www.cognition.us ... released version 9.0 of the Cognition Cockpit platform. , “Our whole team has ... Cronin, CEO of Cognition. “We’re thrilled to finally be able to release it ...
(Date:5/18/2017)... (PRWEB) , ... May 17, 2017 , ... ... construction, announced today that their Chief Executive Officer, Maik Jornitz, was recognized as ... UK publication’s Power List celebrates 100 individuals “involved in bettering the pharma industry ...
(Date:5/16/2017)... ... May 16, 2017 , ... Genedata, a leading provider of ... User Group Meetings, which will be held in Boston, Cambridge/UK, Shanghai, and Tokyo. ... screening data analysis and learn about the latest advances in screening technologies and ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):